MedTrace Logo

Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety

NCT04984070 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-10-05

No results posted yet for this study

Summary

The current study intends to establish a prediction method and evaluation system for polycystic ovary syndrome (PCOS) complicated with affective disorder, such as depression and anxiety, through the epidemiological investigation. Randomized controlled studies on the efficacy of various intervention methods should be carried out to develop early intervention measures and methods in order to reduce the harm of psychological disorders, to facilitate the mental health of PCOS patients, and thus to improve the quality of life.

Conditions

  • PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
  • Depression, Anxiety

Interventions

DRUG

Oral Contraceptives, Combined

One of the three medications like ethinylestradiol (35 μg) and cyproterone acetate, drospirenone and ethinylestradiol tablets (I) and (Ⅱ) will be used as an antiandrogen.

DRUG

Metformin Pill

Metformin is used to lower insulin resistance or to modulate hyperinsulinism.

OTHER

lifestyle intervention

Weight control including calorie restriction and moderate exercise will be recommended to obese PCOS patients

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Wei Zhang, Doctor · OB & GYN Hospital of Fudan University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04984070 on ClinicalTrials.gov